Toll-Like Receptor 7 Mediates Inflammation Resolution and Inhibition of Angiogenesis in Non-Small Cell Lung Cancer

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Pattern recognition receptors (PRRs) modulate inflammation and its resolution.
• Formyl peptide receptor 1 (FPR1) has demonstrated anti-angiogenic and anti-tumor properties in gastric cancer.
• Toll-like receptor 7 (TLR7) is recognized for its role in resolving airway inflammation.

Purpose of the Study:

• To investigate the role of TLR7 in the pro-resolving and anti-angiogenic responses within non-small cell lung cancer (NSCLC).
• To explore the potential of TLR7 as a therapeutic target for inhibiting tumor angiogenesis in NSCLC.

Main Methods:

• RNA sequencing analysis of NSCLC patient data to correlate TLR7 expression with inflammatory mediators.
• In vitro studies using NSCLC cells involving TLR7 depletion and activation.
• Quantitative PCR (qPCR), ELISA, protein arrays, and endothelial cell assays to assess angiogenic and pro-resolving mediator levels.
• Western blotting and inhibitor studies to identify key signaling pathways (MAPK, STAT3).

Main Results:

• TLR7 expression positively correlated with pro-resolving mediators and negatively with angiogenic mediators in NSCLC patients.
• TLR7 depletion in NSCLC cells led to increased angiogenic mediators and enhanced endothelial cell vasculogenesis.
• TLR7 activation demonstrated opposing effects, reducing angiogenesis and increasing pro-resolving potential.
• MAPK and STAT3 signaling pathways were identified as crucial regulators of these TLR7-mediated effects.

Conclusions:

• TLR7 plays a significant role in sustaining a pro-resolving signaling pathway within lung cancer.
• This TLR7-mediated signaling effectively inhibits tumor angiogenesis.
• Targeting TLR7 presents a promising novel therapeutic avenue for NSCLC treatment by modulating the tumor microenvironment and inhibiting angiogenesis.